AbbVie Inc. is a global research-based biopharmaceutical company headquartered in North Chicago, Illinois, formed in 2013 through the separation from Abbott Laboratories. The company discovers, develops, and manufactures therapies across immunology, oncology, neuroscience, eye care, virology, and aesthetics. Its portfolio includes adalimumab (Humira), risankizumab (Skyrizi), upadacitinib (Rinvoq), ibrutinib (Imbruvica, with Janssen), venetoclax (Venclexta, with Roche), and, following the 2020 acquisition of Allergan, products in medical aesthetics and ophthalmology. AbbVie is listed on the New York Stock Exchange under the ticker ABBV.
For the broader chemicals value chain, AbbVie’s operations span small‑molecule and biologics R&D, process development, and large‑scale manufacturing. Capabilities include API synthesis, cell culture and microbial fermentation for monoclonal antibodies and other biologics, as well as fill‑finish and packaging. The company runs a global manufacturing and supply network across the Americas, Europe, and Asia and operates under Good Manufacturing Practice (GMP) standards. AbbVie also engages in partnerships and licensing to advance pipeline candidates and technologies relevant to complex formulations, antibody engineering, and other advanced modalities.